Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan has signed a licensing and settlement deal with Hoffman La Roche to resolve the patent dispute on Xeloda Tablets, 150mg and 500mg, USP, generically known as Capecitabine Tablets.
Subscribe to our email newsletter
Xeloda Tablets, 150mg and 500mg, USP are indicated as a treatment of metastatic breast and colorectal cancers.
Pursuant to the agreement, the litigation was dismissed on 21 September 2011.
Further, the terms of the agreement were not disclosed.